X4 PHARMACEUTICALS, INC Net Income
X4 PHARMACEUTICALS, INC (XFOR) reported Net Income of -$16.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$16.16M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$20.24M, a 7277.66% decline year-over-year.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$23.93M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$29.82M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for fiscal 2025 was -$79.20M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for fiscal 2024 was -$37.45M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for fiscal 2023 was -$101.17M.
- X4 PHARMACEUTICALS, INC net income (loss) attributable to parent for fiscal 2022 was -$93.87M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$16.16M 10-Q · filed 2026-08-06 | -$36.40M 10-Q · filed 2026-08-06 | -$60.32M derived: sum of 3 quarters · filed 2026-08-06 | -$90.14M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$20.24M 10-Q · filed 2026-08-06 | -$44.17M derived: sum of 2 quarters · filed 2026-08-06 | -$73.98M derived: sum of 3 quarters · filed 2026-08-06 | -$99.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$23.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$53.74M derived: sum of 2 quarters · filed 2026-03-17 | -$79.48M derived: sum of 3 quarters · filed 2026-08-06 | -$79.20M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | -$29.82M 10-Q · filed 2025-11-05 | -$55.56M derived: sum of 2 quarters · filed 2026-08-06 | -$55.27M 10-Q · filed 2025-11-05 | -$95.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$25.74M 10-Q · filed 2026-08-06 | -$25.46M 10-Q · filed 2026-08-06 | -$65.28M derived: sum of 3 quarters · filed 2026-08-06 | -$101.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $282.00K 10-Q · filed 2026-08-06 | -$39.54M derived: sum of 2 quarters · filed 2026-08-06 | -$76.23M derived: sum of 3 quarters · filed 2026-08-06 | $14.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | -$39.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$76.52M derived: sum of 2 quarters · filed 2026-03-17 | $14.32M derived: sum of 3 quarters · filed 2026-03-17 | -$37.45M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$36.70M 10-Q · filed 2025-11-05 | $54.14M derived: sum of 2 quarters · filed 2025-11-05 | $2.37M 10-Q · filed 2025-11-05 | -$16.76M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-06-30 | $90.83M 10-Q · filed 2025-11-05 | $39.07M 10-Q · filed 2025-08-08 | $19.94M derived: sum of 3 quarters · filed 2026-03-17 | $17.63M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-03-31 | -$51.77M 10-Q · filed 2025-11-05 | -$70.90M derived: sum of 2 quarters · filed 2026-03-17 | -$73.20M derived: sum of 3 quarters · filed 2026-03-17 | -$128.91M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2023-12-31 | -$19.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$21.43M derived: sum of 2 quarters · filed 2026-03-17 | -$77.15M derived: sum of 3 quarters · filed 2026-03-17 | -$101.17M 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | -$2.31M 10-Q · filed 2024-11-13 | -$58.02M derived: sum of 2 quarters · filed 2024-11-13 | -$82.04M 10-Q · filed 2024-11-13 | -$111.14M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-06-30 | -$55.71M 10-Q · filed 2024-11-13 | -$79.73M 10-Q · filed 2024-08-08 | -$108.84M derived: sum of 3 quarters · filed 2025-03-26 | -$130.42M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-03-31 | -$24.02M 10-Q · filed 2024-11-13 | -$53.12M derived: sum of 2 quarters · filed 2025-03-26 | -$74.71M derived: sum of 3 quarters · filed 2025-03-26 | -$95.92M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2022-12-31 | -$29.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$50.69M derived: sum of 2 quarters · filed 2025-03-26 | -$71.90M derived: sum of 3 quarters · filed 2025-03-26 | -$93.87M 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | -$21.59M 10-Q · filed 2023-11-09 | -$42.80M derived: sum of 2 quarters · filed 2023-11-09 | -$64.76M 10-Q · filed 2023-11-09 | -$94.97M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | -$21.21M 10-Q · filed 2023-11-09 | -$43.18M 10-Q · filed 2023-08-10 | -$73.38M derived: sum of 3 quarters · filed 2024-03-21 | -$93.56M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | -$21.96M 10-Q · filed 2023-11-09 | -$52.17M derived: sum of 2 quarters · filed 2024-03-21 | -$72.35M derived: sum of 3 quarters · filed 2024-03-21 | -$91.98M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | -$30.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$50.38M derived: sum of 2 quarters · filed 2024-03-21 | -$70.02M derived: sum of 3 quarters · filed 2024-03-21 | -$88.70M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | -$20.18M 10-Q · filed 2022-11-03 | -$39.81M derived: sum of 2 quarters · filed 2022-11-03 | -$58.49M 10-Q · filed 2022-11-03 | -$76.89M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | -$19.64M 10-Q · filed 2022-11-03 | -$38.31M 10-Q · filed 2022-08-04 | -$56.71M derived: sum of 3 quarters · filed 2023-03-21 | -$74.16M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | -$18.68M 10-Q · filed 2022-11-03 | -$37.08M derived: sum of 2 quarters · filed 2023-03-21 | -$54.52M derived: sum of 3 quarters · filed 2023-03-21 | -$69.67M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | -$18.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$35.85M derived: sum of 2 quarters · filed 2023-03-21 | -$50.99M derived: sum of 3 quarters · filed 2023-03-21 | -$62.13M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | -$17.45M 10-Q · filed 2021-11-04 | -$32.59M derived: sum of 2 quarters · filed 2021-11-04 | -$43.73M 10-Q · filed 2021-11-04 | -$54.57M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | -$15.14M 10-Q · filed 2021-11-04 | -$26.28M 10-Q · filed 2021-08-03 | -$37.12M derived: sum of 3 quarters · filed 2022-03-17 | -$54.83M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | -$11.14M 10-Q · filed 2021-11-04 | -$21.98M derived: sum of 2 quarters · filed 2022-03-17 | -$39.69M derived: sum of 3 quarters · filed 2022-03-17 | -$53.07M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | -$10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$28.55M derived: sum of 2 quarters · filed 2022-03-17 | -$41.93M derived: sum of 3 quarters · filed 2022-03-17 | -$52.81M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | -$17.71M 10-Q · filed 2020-11-05 | -$31.10M derived: sum of 2 quarters · filed 2020-11-05 | -$41.97M 10-Q · filed 2020-11-05 | -$51.33M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$13.38M 10-Q · filed 2020-11-05 | -$24.26M 10-Q · filed 2020-08-04 | -$33.61M derived: sum of 3 quarters · filed 2020-11-05 | -$42.22M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | -$10.87M 10-Q · filed 2020-11-05 | -$20.23M derived: sum of 2 quarters · filed 2020-11-05 | -$28.83M derived: sum of 3 quarters · filed 2020-11-05 | -$34.87M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2018-12-31 | -$9.36M 10-K · filed 2019-03-11 | -$17.96M derived: sum of 2 quarters · filed 2019-11-07 | -$23.99M derived: sum of 3 quarters · filed 2019-11-07 | -$33.28M 10-K · filed 2021-03-19 | -$43.02M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | -$8.60M 10-Q · filed 2019-11-07 | -$10.90M 10-Q · filed 2018-11-09 | -$14.64M derived: sum of 2 quarters · filed 2019-11-07 | -$22.00M 10-Q · filed 2019-11-07 | -$33.66M 10-Q · filed 2018-11-09 | -$33.19M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | -$6.03M 10-Q · filed 2019-11-07 | -$12.13M 10-Q · filed 2018-08-13 | -$13.40M 10-Q · filed 2019-08-07 | -$22.76M 10-Q · filed 2018-08-13 | -$24.59M derived: sum of 3 quarters · filed 2019-11-07 | -$36.19M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-03-31 | -$7.37M 10-Q · filed 2019-11-07 | -$10.63M 10-Q · filed 2018-05-10 | -$18.55M derived: sum of 2 quarters · filed 2019-11-07 | -$30.15M derived: sum of 3 quarters · filed 2019-11-07 | -$35.86M derived: sum of 4 quarters · filed 2019-11-07 | |||
| 2017-12-31 | -$11.19M 10-K · filed 2019-03-11 | -$22.79M derived: sum of 2 quarters · filed 2019-03-11 | -$28.49M derived: sum of 3 quarters · filed 2019-03-11 | -$21.99M 10-K · filed 2020-03-12 | -$33.88M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | -$11.60M 10-K · filed 2019-03-11 | -$17.30M derived: sum of 2 quarters · filed 2019-03-11 | -$22.69M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | -$5.71M 10-K · filed 2019-03-11 | -$11.09M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | -$5.38M 10-K · filed 2019-03-11 | |||||||
| 2016-12-31 | -$22.98M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |